Clinique Du Parc
- Address
- 50 Rue Emile Combes, 34170 Castelnauv Le Lez, France
Clinique Du Parc - Urologic Oncology Research Center
Clinique Du Parc is a specialized medical research facility dedicated to advancing treatment options for patients with urologic malignancies. The center demonstrates particular expertise in investigating innovative therapeutic approaches for bladder cancer, focusing on patients with challenging disease presentations who have exhausted standard treatment options.
- Non-Muscle Invasive Bladder Cancer (NMIBC) treatment strategies for BCG-unresponsive disease
- Combination immunotherapy and intravesical targeted delivery systems
- Clinical outcomes research in high-risk urothelial carcinoma patients
The center's research portfolio emphasizes the development of novel treatment modalities for patients with high-risk non-muscle invasive urothelial carcinoma who are not candidates for radical cystectomy. Their clinical investigations include evaluating TAR-200 intravesical delivery systems combined with checkpoint inhibitor immunotherapy, representing cutting-edge approaches to preserving bladder function while achieving complete response in patients with carcinoma in situ and papillary disease presentations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinique Du Parc
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of TAR-200 and Cetrelimab in High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin | Janssen Cilag International | Phase II | Not Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azacitidine | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.